Eric Seree
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eric Seree has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Y. Barra
FRE Centre National de la Recherche Scientifique 2737, Faculté de Pharmacie, Marseille, France
3 shared publicationsYves Barra
INRA, UMR1260, Nutriments Lipidiques et Prévention des Maladies Métaboliques, Marseille, France
3 shared publicationsB. Charvet
UPRES A CNRS 6032, Université de la Méditerranée, Faculté de Pharmacie, 27 boulevard Jean Moulin, 13385 Marseille Cedex 05 France
2 shared publicationsB. Lacarelle
FRE Centre National de la Recherche Scientifique 2737, Faculté de Pharmacie, Marseille, France
2 shared publications- Jean-Marc Pascussi
Centre National de la Recherche Scientifique, UMR5203, Institut de Génomique Fonctionnelle, Montpellier, France
2 shared publications Nolwen Guigal
UMR CNRS 6032, Faculté de Pharmacie, Université Méditerranée, 27 boulevard Jean Moulin, FR-13385, Marseille Cédex, France
2 shared publications
Latest Publications
- Open Access
- 31 January 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (1) , e14629
CYP1A1 Induction in the Colon by Serum: Involvement of the PPARα Pathway and Evidence for a New Specific Human PPREα Site
We previously showed that blood serum induced cytochrome P450 1A1 (CYP1A1) monooxygenase expression in vitro. Our purpose was (i) to identify the molecular mechanism involved and (ii) to characterize the inducer compound(s) in serum involved at least in part. Serum was fractionated on hydrophobic columns. PPARα involvement was demonstrated by gene reporter assays, DNA mutagenesis and EMSA. Gene expression was evaluated by qRT-PCR. Serum samples were analyzed using HS-SPME-GC-MS. The inductive effect of serum did not depend on the AhR pathway and was enhanced by cotransfection of PPARα cDNA. Mutations in the PPAR response elements of the CYP1A1 gene promoter suppressed this effect. One of the PPRE sites appeared highly specific for human PPARα, an unreported PPRE property. A link was found between CYP1A1 inducibility and serum hydrophobic compounds. Characterization of sera showed that hexanal, a metabolite produced by peroxidation of linoleic acid, was involved in CYP1A1 induction by serum, possibly along with other serum entities. We demonstrate that serum induces CYP1A1 via the PPARα pathway and that hexanal is one of the serum inducers. The two PPRE sites within the CYP1A1 promoter are functional and one of them is specific for PPARα.
- 31 January 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (1) , e14629
Open AccessCYP1A1 Induction in the Colon by Serum: Involvement of the PPARα Pathway and Evidence for a New Specific Human PPREα Site
We previously showed that blood serum induced cytochrome P450 1A1 (CYP1A1) monooxygenase expression in vitro. Our purpose was (i) to identify the molecular mechanism involved and (ii) to characterize the inducer compound(s) in serum involved at least in part. Serum was fractionated on hydrophobic columns. PPARα involvement was demonstrated by gene reporter assays, DNA mutagenesis and EMSA. Gene expression was evaluated by qRT-PCR. Serum samples were analyzed using HS-SPME-GC-MS. The inductive effect of serum did not depend on the AhR pathway and was enhanced by cotransfection of PPARα cDNA. Mutations in the PPAR response elements of the CYP1A1 gene promoter suppressed this effect. One of the PPRE sites appeared highly specific for human PPARα, an unreported PPRE property. A link was found between CYP1A1 inducibility and serum hydrophobic compounds. Characterization of sera showed that hexanal, a metabolite produced by peroxidation of linoleic acid, was involved in CYP1A1 induction by serum, possibly along with other serum entities. We demonstrate that serum induces CYP1A1 via the PPARα pathway and that hexanal is one of the serum inducers. The two PPRE sites within the CYP1A1 promoter are functional and one of them is specific for PPARα.
- 1 November 2004
- Published by Elsevier in Gastroenterology
- Vol. 127 (5) , 1436-1445
Evidence for a new human CYP1A1 regulation pathway involving PPAR-α and 2 PPRE sites
- 1 November 2004
- Published by Elsevier in Gastroenterology
- Vol. 127 (5) , 1436-1445
Evidence for a new human CYP1A1 regulation pathway involving PPAR-α and 2 PPRE sites
- 11 September 2002
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 297 (2) , 249-254
Serum increases CYP1A1 induction by 3-methylcholanthrene
- 11 September 2002
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 297 (2) , 249-254
Serum increases CYP1A1 induction by 3-methylcholanthrene
- 1 March 2001
- Published by Elsevier in Life Sciences
- Vol. 68 (18) , 2141-2150
Serum induces a transcriptional activation of CYP1A1 gene in HepG2 independently of the AhR pathway.
- 1 March 2001
- Published by Elsevier in Life Sciences
- Vol. 68 (18) , 2141-2150
Serum induces a transcriptional activation of CYP1A1 gene in HepG2 independently of the AhR pathway.
- 1 January 1999
- Published by Elsevier in Life Sciences
- Vol. 64 (10) , 827-835
Metabolism of carbamazepine by CYP3A6: A model for in vitro drug interactions studies
- 1 January 1999
- Published by Elsevier in Life Sciences
- Vol. 64 (10) , 827-835
Metabolism of carbamazepine by CYP3A6: A model for in vitro drug interactions studies
- 1 November 1998
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 252 (2) , 392-395
Modulation of MDR1 and CYP3A Expression by Dexamethasone: Evidence for an Inverse Regulation in Adrenals
- 1 November 1998
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 252 (2) , 392-395
Modulation of MDR1 and CYP3A Expression by Dexamethasone: Evidence for an Inverse Regulation in Adrenals
- 1 November 1993
- Vol. 53 (21) , 5121-6
Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.
Vinblastine biotransformation was investigated by using a human liver microsomes library. The drug was converted into one major metabolite (M) upon incubation with the microsomes. A large interindividual variation in vinblastine metabolism was observed among the samples tested, with a 4.4 ratio between the lowest and the highest metabolic rates. The biotransformation of vinblastine followed Michaelis-Menten kinetics (Km = 6.82 +/- 0.27 microM and Vmax = 0.64 +/- 0.06 nmol/min/mg protein). The involvement of the cytochrome P450 3A subfamily in vinblastine metabolism was demonstrated by the following body of evidence: (a) the competitive inhibition of vinblastine biotransformation by cytochrome P450 3A specific probes with Ki values of 0.17, 22.5, 14.8, and 35.3 microM for ketoconazole, erythromycin, troleandomycin, and vindesine, respectively; (b) the immunoinhibition of vinblastine metabolism by polyclonal anti-cytochrome P450 3A antibodies; (c) the highly significant correlation between the level of cytochrome P450 3A determined by Western blots and vinblastine metabolism (r = 0.759, P < 0.001); (d) the highly significant correlation between erythromycin N-demethylase activity (mediated by cytochrome P450 3A) and vinblastine metabolism (r = 0.83, P < 0.001); (e) the significant correlation between the CYP3A4 mRNA level and vinblastine metabolism (r = 0.60, P < 0.1). Although vincristine and navelbine (members of the Vinca alkaloid family) also inhibit the metabolism of vinblastine, suggesting the involvement of the cytochrome subfamily in their respective metabolisms, other anticancer drugs currently associated with vinblastine in chemotherapy (etoposide, Adriamycin, lomustine, and teniposide) also interfere with vinblastine biotransformation. These metabolic drug interactions may alter the antitumor activity and/or toxicity of the drug during anticancer chemotherapy.
- 1 November 1993
- Vol. 53 (21) , 5121-6
Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.
Vinblastine biotransformation was investigated by using a human liver microsomes library. The drug was converted into one major metabolite (M) upon incubation with the microsomes. A large interindividual variation in vinblastine metabolism was observed among the samples tested, with a 4.4 ratio between the lowest and the highest metabolic rates. The biotransformation of vinblastine followed Michaelis-Menten kinetics (Km = 6.82 +/- 0.27 microM and Vmax = 0.64 +/- 0.06 nmol/min/mg protein). The involvement of the cytochrome P450 3A subfamily in vinblastine metabolism was demonstrated by the following body of evidence: (a) the competitive inhibition of vinblastine biotransformation by cytochrome P450 3A specific probes with Ki values of 0.17, 22.5, 14.8, and 35.3 microM for ketoconazole, erythromycin, troleandomycin, and vindesine, respectively; (b) the immunoinhibition of vinblastine metabolism by polyclonal anti-cytochrome P450 3A antibodies; (c) the highly significant correlation between the level of cytochrome P450 3A determined by Western blots and vinblastine metabolism (r = 0.759, P < 0.001); (d) the highly significant correlation between erythromycin N-demethylase activity (mediated by cytochrome P450 3A) and vinblastine metabolism (r = 0.83, P < 0.001); (e) the significant correlation between the CYP3A4 mRNA level and vinblastine metabolism (r = 0.60, P < 0.1). Although vincristine and navelbine (members of the Vinca alkaloid family) also inhibit the metabolism of vinblastine, suggesting the involvement of the cytochrome subfamily in their respective metabolisms, other anticancer drugs currently associated with vinblastine in chemotherapy (etoposide, Adriamycin, lomustine, and teniposide) also interfere with vinblastine biotransformation. These metabolic drug interactions may alter the antitumor activity and/or toxicity of the drug during anticancer chemotherapy.